UCB Sa operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares UCB Sa with three other
pharmaceutical manufacturers in Europe:
Stada Arzneimittel AG
sales of 2.31 billion Euro [US$2.72 billion]
of which 59%
(258.45 billion Russian Rubles [US$3.87 billion]
of which 78%
was Distribution), and
Lonza Group AG
based in Switzerland
(5.11 billion Swiss Francs [US$5.30 billion]
of which 47%
was Specialty Ingredients).
UCB Sa reported sales of 4.53 billion Euro (US$5.32 billion)
December of 2017.
increase of 8.4%
versus 2016, when the company's sales were 4.18 billion Euro.
This was the third consecutive year of growth at UCB Sa.